Chembio Files For FDA Emergency Use Nod For COVID-19 Antigen Test

by Vandana Singh, Benzinga Editor

November 17, 2021 8:19 AM | 1 min read |

Chembio Diagnostics Inc CEMI submitted an Emergency Use Authorization (EUA) application to the FDA for the new DPP SARS-CoV-2 Antigen test.
The DPP SARS-CoV-2 Antigen test system has been designed to detect COVID-19 antigens in 20 minutes.
See here Benzinga's Full FDA Calendar.
The DPP SARS-CoV-2 Antigen test system is now designed to use a minimally invasive nasal swab and be read visually or with a DPP Micro Reader or DPP Micro Reader 2 optical analyzer.
Chembio submitted a EUA application to the FDA for its DPP Respiratory Antigen Panel test system in September.
Related Link: Chembio Stock More Than Doubles On $28M Purchase Order For Its COVID Antigen Tests.
Price Action: CEMI shares are up 4.85% at $2.16 during the premarket session on the last check Wednesday.

Posted In: Long Ideas News Penny Stocks Health Care FDA Movers Trading Ideas General Briefs COVID-19 Coronavirus Diagnostics

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.